Multiple Sclerosis Therapeutics Market Analysis, Dynamics, Forecast and Supply Demand 2025
Author : Aarti Murkute | Published On : 19 Aug 2021
Multiple sclerosis has long been among the leading cause of neurological disabilities worldwide and the direct and indirect costs associated with it remain a major challenge in the multiple sclerosis therapeutics market. Nonetheless, an uptick in the patients suffering from relapsing remitting multiple sclerosis RRMS) and secondary progressive multiple sclerosis (SPMS) should spur adoption of therapeutics equipment.
For More Insights into the Market, Get Sample Copy of this Report: https://www.fairfieldmarketresearch.com/report/multiple-sclerosis-therapeutics-market/
Lack of Trust in Generic Molecules Poses Problems in Multiple Sclerosis Therapeutics Market
The critical need for rapid-action drugs in the progressive multiple sclerosis sector is the key driver in the multiple sclerosis therapeutics market. For e.g. – Biogen Idec launched Plegridy – a long-acting variant of its interferon Avonex. Healthcare marketers must improve the safety, tolerability, and dosage of their offerings in the multiple sclerosis therapeutics market. A lack of trust due to generic molecules and biosimilars, coupled with prohibitive costs are detrimental to growth in the multiple sclerosis therapeutics market. The Blue Cross/ Blue Shield estimates that multiple sclerosis drugs in the U.S are more than twice the price of other drugs.
Hormonal Differences Make Women Significantly More Vulnerable Than Men to RRMS
The vast majority of multiple sclerosis cases are relapsing remitting multiple sclerosis. RRMS involves episodes of increasing symptoms that are followed by periods of remission. In 2013, a study conducted by the International Progressive Alliance stated that women are three times more vulnerable than men to RRMS. RRMS typically follows a clinically isolated syndrome (CIS) – with symptoms that are longer than a day. In addition, approx. half of patients progress to SPMS within a decade of being diagnosed with RRMS.
In Order to place the Purchase Query Click Here: email@example.com
Convenience of Oral Therapies Explain Their Popularity in the Multiple Sclerosis Therapeutics Market
Disease modifying therapies usually target RRMS and SPMS in the multiple sclerosis therapeutics market. In terms of treatment options, consumers have expressed a clear preference for oral therapies in lieu of injectable ones. Gilenya began the oral therapy boom in 2011 and consolidated its competitive position two years later with Tecfidera – the current leader in the multiple sclerosis therapeutics market. However, oral therapies have been unable to dislodge self-injectable medication from their dominant position in the multiple sclerosis therapeutics market.
A trend of note in the multiple sclerosis therapeutics market has been the growth of infusion therapy. In 2013, Lemtrada – a drug to treat multiple sclerosis was granted regulatory approval by the European Medicines Agency (EMA). Presently, Ocrevus is the only drug approved by the FDA for treating PPMS. Newer compounds such as Zeposia and Kesimpta are likely to intensify competition in the multiple sclerosis therapeutics market. Drugs in phase three clinical trials include Fenebrutinib and Tolebrutinib.
Cash-rich Companies Leave Rivals in Dust in Multiple Sclerosis Therapeutics Market
The three most prescribed brand-name drugs in the multiple sclerosis therapeutics market are Biogen’s Tecfidera, Novartis’ Gilenya, and Roche Holding’s Ocrevus in that order respectively. Experts predict that Ocrevus has extremely promising growth prospects and should gain market share at the expense of its closest rivals. Other major brand-name drugs in the multiple sclerosis therapeutics market comprise Tysabri and Avonex (Biogen Inc.), Copaxone (Teva Pharmaceutical Industries Ltd.), Rebif (Merck KGaA), Aubagio and Lemtrada (Sanofi S.A.), and Betaferon (Bayer AG).
Browse Our Latest Reports: https://www.fairfieldmarketresearch.com/shop/
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.